当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Discontinuation of melanoma combination immunotherapy
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30668-x Holly Baker
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30668-x Holly Baker
Patients with advanced melanoma might continue to benefit from combination immunotherapy even after treatment is stopped because of adverse events, a new study suggests.
中文翻译:
终止黑色素瘤联合免疫治疗
一项新的研究表明,即使由于不良事件而停止治疗后,晚期黑色素瘤患者仍可能继续受益于联合免疫疗法。
更新日期:2017-09-04
中文翻译:
终止黑色素瘤联合免疫治疗
一项新的研究表明,即使由于不良事件而停止治疗后,晚期黑色素瘤患者仍可能继续受益于联合免疫疗法。